Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 2548 results for methods

  1. What is the clinical and cost effectiveness of cognitive behavioural therapy (CBT) for adults with tinnitus delivered by appropriately trained healthcare professionals other than psychologists (for example, audiologists)?

    view that these expensive interventions should only be used when other methods (digital CBT and group-based interventions) have been...

  2. What is the clinical and cost effectiveness of psychological therapies for children and young people who have tinnitus-related distress?

    view that these expensive interventions should only be used when other methods (digital CBT and group-based interventions) have been...

  3. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued Reference number: GID-TA10026

  4. ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

    Discontinued Reference number: GID-TA10445

  5. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development Reference number: GID-TA10843 Expected publication date: TBC

  6. Service user experience in adult mental health: improving the experience of care for people using adult NHS mental health services (CG136)

    This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.

  7. Hepatitis B (chronic): diagnosis and management (CG165)

    This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

  8. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued Reference number: GID-MT510

  9. Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)

    Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.

  10. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

  11. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development Reference number: GID-TA10826 Expected publication date: TBC

  12. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued Reference number: GID-TA10332

  13. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued Reference number: GID-TA10298

  14. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.

  15. Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]

    Discontinued Reference number: GID-TA10869